RESUMO
BACKGROUND: Coronavirus Disease 2019 (COVID-19), firstly reported in China last November 2019, became a global pandemic. It has been shown that periods of isolation may induce a spike in alcohol use disorder (AUD). In addition, alcohol-related liver disease (ALD) is the most common consequence of excessive alcohol consumption worldwide. Moreover, liver impairment has also been reported as a common manifestation of COVID-19. AIMS: The aim of our position paper was to consider some critical issues regarding the management of ALD in patients with AUD in the era of COVID-19. METHODS: A panel of experts of the Italian Society of Alcohology (SIA) met via "conference calls" during the lockdown period to draft the SIA's criteria for the management of ALD in patients with COVID-19 as follows: (a) liver injury in patients with ALD and COVID-19 infection; (b) toxicity to the liver of the drugs currently tested to treat COVID-19 and the pharmacological interaction between medications used to treat AUD and to treat COVID-19; (c) reorganization of the management of compensated and decompensated ALD and liver transplantation in the COVID-19 era. RESULTS AND CONCLUSIONS: The COVID-19 pandemic has rapidly carried us toward a new governance scenario of AUD and ALD which necessarily requires an in-depth review of the management of these diseases with a new safe approach (management of out-patients and in-patients following new rules of safety, telemedicine, telehealth, call meetings with clinicians, nurses, patients, and caregivers) without losing the therapeutic efficacy of multidisciplinary treatment.
Assuntos
Alcoolismo , COVID-19 , Hepatopatias Alcoólicas , Alcoolismo/complicações , Alcoolismo/epidemiologia , Alcoolismo/terapia , Controle de Doenças Transmissíveis , Humanos , Hepatopatias Alcoólicas/epidemiologia , Hepatopatias Alcoólicas/terapia , PandemiasRESUMO
Coronavirus disease 2019 (COVID-19) first emerged in China in November 2019. Most governments have responded to the COVID-19 pandemic by imposing a lockdown. Some evidence suggests that a period of isolation might have led to a spike in alcohol misuse, and in the case of patients with alcohol use disorder (AUD), social isolation can favour lapse and relapse. The aim of our position paper is to provide specialists in the alcohol addiction field, in psychopharmacology, gastroenterology and in internal medicine, with appropriate tools to better manage patients with AUD and COVID-19,considering some important topics: (a) the susceptibility of AUD patients to infection; (b) the pharmacological interaction between medications used to treat AUD and to treat COVID-19; (c) the reorganization of the Centre for Alcohol Addiction Treatment for the management of AUD patients in the COVID-19 era (group activities, telemedicine, outpatients treatment, alcohol-related liver disease and liver transplantation, collecting samples); (d) AUD and SARS-CoV-2 vaccination. Telemedicine/telehealth will undoubtedly be useful/practical tools even though it remains at an elementary level; the contribution of the family and of caregivers in the management of AUD patients will play a significant role; the multidisciplinary intervention involving experts in the treatment of AUD with specialists in the treatment of COVID-19 disease will need implementation. Thus, the COVID-19 pandemic is rapidly leading addiction specialists towards a new governance scenario of AUD, which necessarily needs an in-depth reconsideration, focusing attention on a safe approach in combination with the efficacy of treatment.
Assuntos
Alcoolismo/terapia , COVID-19/prevenção & controle , Controle de Doenças Transmissíveis , Alcoólicos Anônimos , Alcoolismo/epidemiologia , Assistência Ambulatorial/organização & administração , COVID-19/epidemiologia , Vacinas contra COVID-19/uso terapêutico , Atenção à Saúde/organização & administração , Suscetibilidade a Doenças , Interações Medicamentosas , Humanos , Terapia de Imunossupressão/efeitos adversos , Itália/epidemiologia , Cirrose Hepática Alcoólica/epidemiologia , Cirrose Hepática Alcoólica/terapia , Transplante de Fígado , Recidiva , SARS-CoV-2 , Sociedades Médicas , Telemedicina , Tratamento Farmacológico da COVID-19RESUMO
Current estimates of the prevalence of chronic pancreatitis, one of the most common causes of exocrine pancreatic insufficiency, are in the range of 3-10 per 100,000 people in many parts of the world. Alcohol consumption is a very important risk factor for exocrine pancreatic insufficiency and is involved in nearly half of all cases. The main hypothesis regarding the role of chronic alcohol consumption in pancreatitis is that there must be additional environmental or genetic risk factors involved for ongoing damage to occur. Treatment of patients with alcohol-related exocrine pancreatic insufficiency is complex, as the patient has two concomitant pathologies, alcohol-use disorder (AUD) and exocrine pancreatic insufficiency/chronic pancreatitis. Alcohol abstinence is the starting point for treatment, although even this along with the most advanced therapies allow only a slowdown in progression rather than restoration of function. This position paper of the Italian Association for the Study of the Pancreas and the Italian Society of Alcohology provides an overview of the pathogenesis of alcohol-related pancreatitis and discuss diagnostic issues. Treatment options for both exocrine pancreatic insufficiency/chronic pancreatitis (with a focus on pancreatic enzyme replacement therapy) and AUD (acamprosate, disulfiram, oral naltrexone, long-acting injectable naltrexone, sodium oxybate, nalmefene, baclofen, and psychosocial interventions) are also reviewed.
Assuntos
Etanol/efeitos adversos , Insuficiência Pancreática Exócrina/etiologia , Pancreatite Alcoólica/complicações , Abstinência de Álcool , Dissuasores de Álcool/uso terapêutico , Alcoolismo/complicações , Alcoolismo/tratamento farmacológico , Alcoolismo/terapia , Antioxidantes/uso terapêutico , Gerenciamento Clínico , Progressão da Doença , Terapia de Reposição de Enzimas , Insuficiência Pancreática Exócrina/induzido quimicamente , Insuficiência Pancreática Exócrina/diagnóstico , Insuficiência Pancreática Exócrina/terapia , Feminino , Humanos , Estilo de Vida , Masculino , Oxirredução , Neoplasias Pancreáticas/etiologia , Pancreatite Alcoólica/diagnóstico , Psicoterapia , Fatores de Risco , Grupos de AutoajudaRESUMO
The chronic use of alcohol can lead to the onset of an alcohol use disorder (AUD). About 50% of subjects with an AUD may develop alcohol withdrawal syndrome (AWS) when they reduce or discontinue their alcohol consumption and, in 3-5% of them, convulsions and delirium tremens (DTs), representing life-threatening complications, may occur. Unfortunately, few physicians are adequately trained in identifying and treating AWS. The Italian Society on Alcohol has, therefore, implemented a task force of specialists to draw up recommendations for the treatment of AWS with the following main results: (1) while mild AWS may not require treatment, moderate and severe AWS need to be pharmacologically treated; (2) out-patient treatment is appropriate in patients with mild or moderate AWS, while patients with severe AWS need to be treated as in-patients; (3) benzodiazepines, BDZs are the "gold standard" for the treatment of AWS and DTs; (4) alpha-2-agonists, beta-blockers, and neuroleptics may be used in association when BDZs do not completely resolve specific persisting symptoms of AWS; (5) in the case of a refractory form of DTs, the use of anaesthetic drugs (propofol and phenobarbital) in an intensive care unit is appropriate; (6) alternatively to BDZs, sodium oxybate, clomethiazole, and tiapride approved in some European Countries for the treatment of AWS may be employed for the treatment of moderate AWS; (7) anti-convulsants are not sufficient to suppress AWS, and they may be used only in association with BDZs for the treatment of refractory forms of convulsions in the course of AWS.
Assuntos
Intoxicação Alcoólica/diagnóstico , Intoxicação Alcoólica/tratamento farmacológico , Benzodiazepinas/uso terapêutico , Síndrome de Abstinência a Substâncias/diagnóstico , Síndrome de Abstinência a Substâncias/tratamento farmacológico , Anticonvulsivantes/uso terapêutico , Clormetiazol/uso terapêutico , Humanos , Fenobarbital/uso terapêutico , Propofol/uso terapêutico , Oxibato de Sódio/uso terapêutico , Cloridrato de Tiaprida/uso terapêuticoRESUMO
Alcoholic liver disease encompasses a broad spectrum of diseases ranging from steatosis steatohepatitis, fibrosis, and cirrhosis to hepatocellular carcinoma. Forty-four per cent of all deaths from cirrhosis are attributed to alcohol. Alcoholic liver disease is the second most common diagnosis among patients undergoing liver transplantation (LT). The vast majority of transplant programmes (85%) require 6 mo of abstinence prior to transplantation; commonly referred to as the "6-mo rule". Both in the case of progressive end-stage liver disease (ESLD) and in the case of severe acute alcoholic hepatitis (AAH), not responding to medical therapy, there is a lack of evidence to support a 6-mo sobriety period. It is necessary to identify other risk factors that could be associated with the resumption of alcohol drinking. The "Group of Italian Regions" suggests that: in a case of ESLD with model for end-stage liver disease < 19 a 6-mo abstinence period is required; in a case of ESLD, a 3-mo sober period before LT may be more ideal than a 6-mo period, in selected patients; and in a case of severe AAH, not responding to medical therapies (up to 70% of patients die within 6 mo), LT is mandatory, even without achieving abstinence. The multidisciplinary transplant team must include an addiction specialist/hepato-alcohologist. Patients have to participate in self-help groups.
Assuntos
Hepatite Alcoólica/cirurgia , Cirrose Hepática Alcoólica/cirurgia , Transplante de Fígado/normas , Abstinência de Álcool , Comorbidade , Hepatite Alcoólica/diagnóstico , Hepatite Alcoólica/mortalidade , Humanos , Itália/epidemiologia , Cirrose Hepática Alcoólica/diagnóstico , Cirrose Hepática Alcoólica/mortalidade , Equipe de Assistência ao Paciente/normas , Seleção de Pacientes , Medição de Risco , Fatores de Risco , Grupos de Autoajuda/normas , Índice de Gravidade de Doença , Fatores de Tempo , Resultado do Tratamento , Listas de EsperaRESUMO
Several experimental studies have suggested that specific nutrients might play a role on the risk of liver damage. Nevertheless, few epidemiological studies have evaluated the role of diet on the risk of symptomatic liver cirrhosis, giving contradictory results. To evaluate the role of the intake of nutritional factors and dietary patterns on the risk of symptomatic liver cirrhosis and to examine their combined action with alcohol consumption we used data from the Italian Study on Liver Cirrhosis Determinants project. From 1994 to 1998 all the consecutive cirrhotic inpatients admitted to 19 Italian collaborative hospitals for signs of liver decompensation in whom the diagnosis of liver cirrhosis was made for the first time (259 cases) and one or two gender, age and area of residence matched individuals (416 controls) were recruited. Data on lifetime alcohol intake, usual consumption of 191 food items and on markers of hepatitis B and C viral infection were collected. The analysis of principal components identified a nutritional pattern positively correlated with vegetable and fruit intakes and negatively with animal and no-fruit sugar products. With respect to abstainers, relative risks in consumers of use < or = 25 and > or = 51 g/day of alcohol increased from 0.4 [95% confidence interval 0.0, 5.9] to 9.3 [1.3, 69.0] and from 2.1 [1.1, 4.2] to 18.1 [2.8, 118.3] for the lowest and the highest value of this nutritional pattern, respectively. Diet might therefore modulate the damaging effect of alcohol on the liver.
Assuntos
Dieta/estatística & dados numéricos , Comportamento Alimentar , Cirrose Hepática/epidemiologia , Cirrose Hepática/etiologia , Avaliação Nutricional , Adulto , Idoso , Consumo de Bebidas Alcoólicas/efeitos adversos , Consumo de Bebidas Alcoólicas/epidemiologia , Estudos de Casos e Controles , Dieta/efeitos adversos , Feminino , Frutas , Anticorpos Anti-Hepatite B/sangue , Anticorpos Anti-Hepatite C/sangue , Hospitalização , Humanos , Entrevistas como Assunto , Itália/epidemiologia , Cirrose Hepática/diagnóstico , Masculino , Pessoa de Meia-Idade , Análise de Componente Principal , Análise de Regressão , Fatores de Risco , Sacarose , VerdurasRESUMO
AIMS: To determine whether the functional A49G polymorphism of cytotoxic T-lymphocyte antigen-4 (CTLA-4), a T-cell surface molecule that modulates T-lymphocyte activation and influences the risk of developing alcohol-induced autoantibodies, plays a role in susceptibility to alcoholic liver disease (ALD) and influences disease severity in Italian alcohol abusers. METHODS: One hundred and eighty-three patients with chronic ALD (61 cirrhosis), 115 end-stage HCV cirrhosis, 102 non-alcoholic fatty liver disease (NAFLD), 93 healthy subjects and 43 heavy drinkers without liver disease were studied. CTLA-4 gene polymorphism was analysed by restriction analysis. RESULTS: The frequency of the CTLA-4 polymorphism was higher in patients with ALD than in patients with HCV chronic hepatitis and NAFLD, healthy subjects (P < 0.0001), and heavy drinkers without liver disease (P = 0.02). In patients with ALD, homozygosity for the CTLA-4 polymorphic allele (G/G genotype) was more represented in subjects with cirrhosis (P = 0.047), and independently associated with the risk of cirrhosis (OR 3.5; P = 0.03). CONCLUSIONS: The CTLA-4 polymorphic G allele, probably by interfering with the immune response, may confer susceptibility to ALD and, in homozygous state, to alcoholic cirrhosis.
Assuntos
Adenina , Antígenos de Diferenciação/genética , Predisposição Genética para Doença/genética , Guanina , Hepatopatias Alcoólicas/genética , Polimorfismo Genético/genética , Adulto , Idoso , Alelos , Antígenos CD , Antígeno CTLA-4 , Feminino , Genótipo , Humanos , Itália/epidemiologia , Hepatopatias Alcoólicas/epidemiologia , Masculino , Pessoa de Meia-Idade , Razão de Chances , Prevalência , Índice de Gravidade de Doença , Linfócitos T Citotóxicos/imunologiaRESUMO
BACKGROUND: Since the mid-1970s, a striking reduction in alcohol consumption has been observed in Italy and other developed countries. Alcohol-related mortality in Italy has been estimated for 1983 and 1996. METHODS: Alcohol-attributable and alcohol-preventable deaths were estimated by: i) data on prevalence of drinkers from two Italian surveys; ii) the parameters of meta-regression models investigating the relationship between alcohol intake and the risk of several conditions positively and negatively related to alcohol; and iii) the number of deaths from 21 alcohol-related conditions. RESULTS: About 68,000 and 42,000 deaths were attributed to alcohol consumption in 1983 and in 1996 respectively, mostly from hemorrhagic stroke, liver cirrhosis, cancer, and injuries. About 6,600 deaths from coronary heart disease were prevented by alcohol. Light intake (25 g/day or less) caused about 30% of deaths attributable to any consumption in women. In men, about one-half of the deaths were attributable to the highest category of intake (100 g/day or more), while a lower proportion of deaths was attributed to light intake (almost 7%). In 1996 the number of the deaths caused and those prevented by light intake was approximately the same (5,400 and 5,200 respectively) and did not significantly differ. CONCLUSION: The estimated number of deaths attributable to alcohol consumption in Italy still far exceeds the number prevented for both women and men. Despite the cardiac protective effect, alcohol consumption remains a major public health problem in Italy. Both population and high risk strategies in preventing alcohol-related problems should be implemented.